tiprankstipranks
Advertisement
Advertisement

GB:SVNS Stock Latest News

Solvonis wins second U.S. patent to deepen PTSD therapy IP
Company AnnouncementsSolvonis wins second U.S. patent to deepen PTSD therapy IP
7d ago
Solvonis Wins Key U.S. Patent to Bolster PTSD Drug Pipeline
PremiumCompany Announcements
Solvonis Wins Key U.S. Patent to Bolster PTSD Drug Pipeline
15d ago
Solvonis names patented PTSD drug candidate SVN‑114 as lead asset
PremiumCompany Announcements
Solvonis names patented PTSD drug candidate SVN‑114 as lead asset
1M ago
Solvonis Extends Novel SDRI SVN‑015 Into Depression After Positive Preclinical Results
PremiumCompany Announcements
Solvonis Extends Novel SDRI SVN‑015 Into Depression After Positive Preclinical Results
3M ago
Solvonis Wins U.S. Patent Boost for Novel PTSD Drug Programme
PremiumCompany Announcements
Solvonis Wins U.S. Patent Boost for Novel PTSD Drug Programme
3M ago
Solvonis Therapeutics Maps Out Catalyst-Rich 2026 as CNS Pipeline Gains Momentum
PremiumCompany AnnouncementsSolvonis Therapeutics Maps Out Catalyst-Rich 2026 as CNS Pipeline Gains Momentum
4M ago
Solvonis’ SVN-015 Accepted into NIDA Program for Addiction Treatment
Premium
Company Announcements
Solvonis’ SVN-015 Accepted into NIDA Program for Addiction Treatment
4M ago
Solvonis Therapeutics Updates Share Capital Details
Premium
Company Announcements
Solvonis Therapeutics Updates Share Capital Details
6M ago
Solvonis Therapeutics Streamlines Operations and Enhances R&D Focus
PremiumCompany Announcements
Solvonis Therapeutics Streamlines Operations and Enhances R&D Focus
6M ago
Solvonis Therapeutics Appoints Paul Carter as Non-Executive Director
PremiumCompany Announcements
Solvonis Therapeutics Appoints Paul Carter as Non-Executive Director
6M ago
Solvonis Therapeutics Raises £1.25 Million to Boost CNS Disorder Programs
PremiumCompany Announcements
Solvonis Therapeutics Raises £1.25 Million to Boost CNS Disorder Programs
6M ago
Solvonis Therapeutics Expands Pipeline with Awakn Acquisition
PremiumCompany Announcements
Solvonis Therapeutics Expands Pipeline with Awakn Acquisition
7M ago
Solvonis Therapeutics Enhances CNS Focus with Exclusive Collaboration and New Equity Issue
PremiumCompany AnnouncementsSolvonis Therapeutics Enhances CNS Focus with Exclusive Collaboration and New Equity Issue
8M ago
Solvonis Therapeutics: Advancing Novel Treatments for Addiction
Premium
Company Announcements
Solvonis Therapeutics: Advancing Novel Treatments for Addiction
8M ago
Solvonis Advances Three Candidates in PTSD Programme
Premium
Company Announcements
Solvonis Advances Three Candidates in PTSD Programme
8M ago
Solvonis Therapeutics Advances PTSD Programme with Promising Preclinical Results
PremiumCompany Announcements
Solvonis Therapeutics Advances PTSD Programme with Promising Preclinical Results
8M ago
Solvonis Therapeutics Advances SVN-002 Towards Phase 2b Trial for AUD
PremiumCompany Announcements
Solvonis Therapeutics Advances SVN-002 Towards Phase 2b Trial for AUD
9M ago
Solvonis Therapeutics Raises Funds Through Warrant Exercise
PremiumCompany Announcements
Solvonis Therapeutics Raises Funds Through Warrant Exercise
9M ago
Solvonis Chair to Highlight Strategic Leadership at Biotech Event
PremiumCompany Announcements
Solvonis Chair to Highlight Strategic Leadership at Biotech Event
9M ago
Solvonis Secures £1 Million to Boost AI Drug Discovery
PremiumCompany AnnouncementsSolvonis Secures £1 Million to Boost AI Drug Discovery
9M ago
Solvonis Therapeutics PLC Announces Change in Major Holdings
Premium
Company Announcements
Solvonis Therapeutics PLC Announces Change in Major Holdings
9M ago
Solvonis Therapeutics Marks Milestone with AGM Success and Strategic Acquisition
Premium
Company Announcements
Solvonis Therapeutics Marks Milestone with AGM Success and Strategic Acquisition
10M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >